Cleave Therapeutics Announces Commencement of a Phase 1 Clinical Study of CB-5339, A Valosin-Containing Protein (VCP)/p97 Inhibitor, in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Cookies are used on our website. Press Accept if you consent to the use of cookies, press Decline if you do not consent to the use of cookies.AcceptDecline